ClinicalTrials.gg
Drug

Fibroblast Growth Factor 7 clinical trials

Also written Palifermin.

studies test it
42
open now
5
in phase 3
8
first study started
2000

How each study uses Fibroblast Growth Factor 7 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Fibroblast Growth Factor 7 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
15 Dec 2004 · KEPIVANCE · BLA 125103 (FDA, Drugs@FDA)
European Union
25 Oct 2005 · Kepivance · EMEA/H/C/000609 (EMA; now withdrawn)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Kepivance
17
Recombinant Human Keratinocyte Growth Factor
7
Keratinocyte growth factor
5
Recombinant Human Keratinocyte Growth Factor (rHuKGF)
4
KGF
3

Other names

Palifermin
33

Studies by the year they started

41 studies that test it; most in 2005 (9)

Studies that test Fibroblast Growth Factor 7, by start year
YearStudies
20001
20011
20021
20059
20065
20074
20083
20092
20104
20122
20153
20201
20241
20253
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
3
Phase 1
19
Phase 2
24
Phase 3
8
Phase 4
1
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 14 · Other 28

Swedish Orphan Biovitrum (11) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Amgen (3) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (1) · University College, London (1) · University of Arizona (1) · Memorial Sloan Kettering Cancer Center (1)

Often tested with

Tested in the same studies.

Busulfan (7) · Melphalan (5) · Fludarabine (4) · Alemtuzumab (4) · Filgrastim (3) · Rituximab (2) · Etoposide (2) · Antilymphocyte Serum (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test Fibroblast Growth Factor 7.

Studies

Open first, then newest update. How each study uses Fibroblast Growth Factor 7 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 42

See all 42 studies that test Fibroblast Growth Factor 7 →

Given beside what is tested · 15 — Fibroblast Growth Factor 7 is usual care or a partner of the new treatment

Codes

What other systems call Fibroblast Growth Factor 7 · ClinicalTrials.gg INT008873

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.